問卷

TPIDB > Principal Investigator

Principal Investigator


Cheng Hsin General Hospital (在職)

Division of Cardiovascular Diseases

更新時間:2023-09-19

曹殿萍
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

4Cases

2021-09-01 - 2027-03-31

Phase III

Active
ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
  • Condition/Disease

    ASCVD, CKD and systemic inflammation

  • Test Drug

    Ziltivekimab B 15 mg/ml / placebo

Participate Sites
12Sites

Recruiting9Sites

Terminated3Sites

2017-02-01 - 2019-05-09

Phase III

Evaluation of the safety and efficacy of an edoxaban-based compared to a vitamin K antagonist-based antithrombotic regimen following successful percutaneous coronary intervention (PCI) with stent placement. (EdoxabaN Treatment versus VKA in patients with AF undergoing PCI ( ENTRUST-AF PCI)
  • Condition/Disease

    Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement

  • Test Drug

    Edoxaban (DU-176b)

Participate Sites
13Sites

Terminated11Sites

江晨恩
Taipei Veterans General Hospital

Division of Cardiovascular Diseases

2010-04-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Study ended7Sites

2009-10-31 - 2013-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites